StockMacro
Menu

Aquestive Therapeutics

$3.46 -15% in 6 monthsMarket cap $434.9M

AQST on XNAS, Health Care, Aquestive Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue fell 41% to $7.6M while short interest stands at 23% of shares.

  • BadNet loss $79.3M over 12 months and free cash outflow $40.7M
  • BadShares down 38% over the last 12 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Industry
Pharmaceutical preparations (Health Care)
Employees
147
Website
aquestive.com
Listed
Nasdaq, US
Last results
3 Nov 2026
Next results
expected around 3 Mar 2027 (an estimate: a year ago it reported on 4 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $7.6M, net loss $16.5M.
Quarter to 31 Dec 2021: revenue $11.1M, net income -$28.9MQuarter to 31 Dec 2021: revenue $11.1M, net income -$28.9MQuarter to 31 Mar 2022: revenue $12.3M, net income -$13.2MQuarter to 31 Mar 2022: revenue $12.3M, net income -$13.2MQuarter to 30 Jun 2022: revenue $13.3M, net income -$16.3MQuarter to 30 Jun 2022: revenue $13.3M, net income -$16.3MQuarter to 30 Sep 2022: revenue $11.5M, net income -$12.5MQuarter to 30 Sep 2022: revenue $11.5M, net income -$12.5MQuarter to 31 Dec 2022: revenue $10.7M, net income -$12.4MQuarter to 31 Dec 2022: revenue $10.7M, net income -$12.4MQuarter to 31 Mar 2023: revenue $11.1M, net income $8.1MQuarter to 31 Mar 2023: revenue $11.1M, net income $8.1MQuarter to 30 Jun 2023: revenue $13.2M, net income -$5.8MQuarter to 30 Jun 2023: revenue $13.2M, net income -$5.8MQuarter to 30 Sep 2023: revenue $13.0M, net income -$2.0MQuarter to 30 Sep 2023: revenue $13.0M, net income -$2.0MQuarter to 31 Dec 2023: revenue $13.2M, net income -$8.1MQuarter to 31 Dec 2023: revenue $13.2M, net income -$8.1MQuarter to 31 Mar 2024: revenue $12.1M, net income -$12.8MQuarter to 31 Mar 2024: revenue $12.1M, net income -$12.8MQuarter to 30 Jun 2024: revenue $20.1M, net income -$2.7MQuarter to 30 Jun 2024: revenue $20.1M, net income -$2.7MQuarter to 30 Sep 2024: revenue $13.5M, net income -$11.5MQuarter to 30 Sep 2024: revenue $13.5M, net income -$11.5MQuarter to 31 Dec 2024: revenue $11.9M, net income -$17.1MQuarter to 31 Dec 2024: revenue $11.9M, net income -$17.1MQuarter to 31 Mar 2025: revenue $8.7M, net income -$22.9MQuarter to 31 Mar 2025: revenue $8.7M, net income -$22.9MQuarter to 30 Jun 2025: revenue $10.0M, net income -$13.5MQuarter to 30 Jun 2025: revenue $10.0M, net income -$13.5MQuarter to 30 Sep 2025: revenue $12.8M, net income -$15.4MQuarter to 30 Sep 2025: revenue $12.8M, net income -$15.4MQuarter to 31 Dec 2025: revenue $13.0M, net income -$31.9MQuarter to 31 Dec 2025: revenue $13.0M, net income -$31.9MQuarter to 31 Mar 2026: revenue $14.4M, net income -$8.1MQuarter to 31 Mar 2026: revenue $14.4M, net income -$8.1MQuarter to 30 Jun 2026: revenue $13.8M, net income -$22.9MQuarter to 30 Jun 2026: revenue $13.8M, net income -$22.9MQuarter to 30 Sep 2026: revenue $7.6M, net income -$16.5MQuarter to 30 Sep 2026: revenue $7.6M, net income -$16.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $31.9M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$7.6M-$16.5M
30 Jun 2026$13.8M-$22.9M
31 Mar 2026$14.4M-$8.1M
31 Dec 2025$13.0M-$31.9M
30 Sep 2025$12.8M-$15.4M
30 Jun 2025$10.0M-$13.5M
31 Mar 2025$8.7M-$22.9M
31 Dec 2024$11.9M-$17.1M
30 Sep 2024$13.5M-$11.5M
30 Jun 2024$20.1M-$2.7M
31 Mar 2024$12.1M-$12.8M
31 Dec 2023$13.2M-$8.1M
30 Sep 2023$13.0M-$2.0M
30 Jun 2023$13.2M-$5.8M
31 Mar 2023$11.1M$8.1M
31 Dec 2022$10.7M-$12.4M
30 Sep 2022$11.5M-$12.5M
30 Jun 2022$13.3M-$16.3M
31 Mar 2022$12.3M-$13.2M
31 Dec 2021$11.1M-$28.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $48.8M $43.4M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +13% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$79.3M -$69.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.65 -$0.71
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 65.3% 60.3% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -114% -129% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -162% -159% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$40.7M -$50.9M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $90.3M $129.1M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $50.8M $45.0M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$39.6M (net cash) -$84.1M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 8.9 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 8.1 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Aquestive TherapeuticsAQST (this company) $434.9Mloss8.9+13%-162%
Indaptus TherapeuticsINDP $433.2Mloss–––
EvolusEOLS $431.5Mloss1.3+14%-9.6%
Capricor TherapeuticsCAPR $441.3Mloss–––
Lyell ImmunopharmaLYEL $441.8Mlossover 999-63%–
CytomX TherapeuticsCTMX $442.5Mloss31.5-88%-609%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$198K

bought $99K, sold $297K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+2.7%

188 13F filers vs 183

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

60%

75.6M shares held by 13F filers (30 Sep 2026) of 125.7M outstanding (30 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

23%

29.3M shares sold short (30 Oct 2026) of 125.7M outstanding (30 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

13.2

29.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+6.2%

27.6M shares sold short in the report before, 29.3M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

68%

68% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 50%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-41%

$7.6M vs $12.8M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$240K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

14

14 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

14×

14 articles in the last 7 days; its usual week has 1.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Revenue $7.6M, -41% vs a year earlier

Price $3.46 on 20 Nov 2026, -38% over 12 months (12-month range $2.95 to $6.62)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $2.3M in the last 12 months (the 12 months before: -$1.7M).
Revenue per quarter. Revenue $7.6M in the latest quarter, -41% on a year earlier.
Capital spending per quarter. Capital spending $584K in the latest quarter, +149% on a year earlier.
Institutional holders (13F filers). 188 13F filers reported holding it in the latest 13F quarter, +31% on a year earlier.
Lobbying spend. Lobbying spend: $240K published in the last 12 months, +140% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
5 Nov 2026Sharp changeQuarterly revenue change: quarterly revenue change, 7.6M vs usual 12.9M (2026-09-30); 0.6x the same period a year earlier
29 Sep 20268-K and other filingsDirector or officer change
29 Sep 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 May 20268-K and other filingsA major agreement ended
20 Mar 20268-K and other filingsDirector or officer change
20 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Mar 2026Sharp changeShort interest spike: short interest spike, 20.0M vs usual 10.7M (2026-02-13); 2.0x the same period a year earlier
17 Feb 2026Sharp changeShort interest spike: short interest spike, 20.4M vs usual 10.7M (2026-01-30); 1.8x the same period a year earlier
3 Feb 2026Sharp changeShort interest spike: short interest spike, 20.3M vs usual 10.7M (2026-01-15); 1.7x the same period a year earlier
13 Jan 2026Sharp changeShort interest spike: short interest spike, 24.1M vs usual 10.4M (2025-12-31); 2.3x the same period a year earlier
30 Dec 2025Sharp changeShort interest spike: short interest spike, 21.9M vs usual 10.1M (2025-12-15); 2.3x the same period a year earlier
16 Dec 2025Sharp changeShort interest spike: short interest spike, 19.8M vs usual 10.1M (2025-11-28); 2.0x the same period a year earlier
2 Dec 2025Sharp changeShort interest spike: short interest spike, 19.2M vs usual 10.0M (2025-11-14); 1.9x the same period a year earlier
18 Nov 2025Sharp changeShort interest spike: short interest spike, 14.7M vs usual 10.0M (2025-10-31); 1.5x the same period a year earlier
20 Oct 2025Sharp changeLobbying on a new issue: lobbying on a new issue: CSP (2025-09-30)
22 Jul 2025Lobbying filingnew lobbying registration (BRACEWELL LLP)
13 May 2025Sharp changeQuarterly revenue change: quarterly revenue change, 8.7M vs usual 13.1M (2025-03-31); 0.7x the same period a year earlier
7 Nov 20248-K and other filingsDirector or officer change
7 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
29 Oct 2024Sharp changeShort interest spike: short interest spike, 10.8M vs usual 3.2M (2024-10-15); 5.4x the same period a year earlier
15 Oct 2024Sharp changeShort interest spike: short interest spike, 11.1M vs usual 2.3M (2024-09-30); 5.4x the same period a year earlier
1 Oct 2024Sharp changeShort interest spike: short interest spike, 10.8M vs usual 2.2M (2024-09-13); 5.8x the same period a year earlier
17 Sep 2024Sharp changeShort interest spike: short interest spike, 10.8M vs usual 2.1M (2024-08-30); 5.9x the same period a year earlier
27 Aug 2024Sharp changeShort interest spike: short interest spike, 10.8M vs usual 2.0M (2024-08-15); 5.5x the same period a year earlier
13 Aug 2024Sharp changeQuarterly revenue change: quarterly revenue change, 20.1M vs usual 12.5M (2024-06-30); 1.5x the same period a year earlier
13 Aug 2024Sharp changeShort interest spike: short interest spike, 10.8M vs usual 2.0M (2024-07-31); 5.3x the same period a year earlier
30 Jul 2024Sharp changeShort interest spike: short interest spike, 10.4M vs usual 2.0M (2024-07-15); 5.4x the same period a year earlier
21 Jul 2024Lobbying filinglobbying engagement terminated (RUBICON ADVISORS, LLC)
16 Jul 2024Sharp changeShort interest spike: short interest spike, 7.6M vs usual 2.0M (2024-06-28); 4.4x the same period a year earlier
2 Jul 2024Sharp changeShort interest spike: short interest spike, 7.2M vs usual 2.0M (2024-06-14); 3.2x the same period a year earlier
18 Jun 2024Sharp changeShort interest spike: short interest spike, 6.7M vs usual 2.0M (2024-05-31); 3.4x the same period a year earlier
6 Jun 20248-K and other filingsDirector or officer change
28 May 2024Sharp changeShort interest spike: short interest spike, 6.2M vs usual 2.0M (2024-05-15); 3.2x the same period a year earlier
21 May 2024Sharp changeMany funds opening a new position: many funds opening a new position, 47 vs usual 5 (2024-03-31); 9.4x the same period a year earlier
14 May 2024Sharp changeShort interest spike: short interest spike, 5.3M vs usual 2.0M (2024-04-30); 2.9x the same period a year earlier
30 Apr 2024Sharp changeShort interest spike: short interest spike, 4.0M vs usual 1.9M (2024-04-15); 2.1x the same period a year earlier
1 Apr 20248-K and other filingsDirector or officer change
1 Apr 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Nov 20238-K and other filingsA major agreement ended
15 Aug 2023Sharp changeMany funds opening a new position: many funds opening a new position, 22 vs usual 5 (2023-06-30); 5.5x the same period a year earlier
18 Jul 2023Lobbying filinglobbying engagement terminated (STEPTOE LLP)
3 Jan 20238-K and other filingsDelisting notice or listing transfer
13 Dec 2022Sharp changeShort interest spike: short interest spike, 2.3M vs usual 1.3M (2022-11-30); 1.9x the same period a year earlier
29 Nov 2022Sharp changeShort interest spike: short interest spike, 2.4M vs usual 1.3M (2022-11-15); 2.1x the same period a year earlier
15 Nov 2022Sharp changeShort interest spike: short interest spike, 2.6M vs usual 1.3M (2022-10-31); 1.8x the same period a year earlier
1 Nov 2022Sharp changeShort interest spike: short interest spike, 2.6M vs usual 1.3M (2022-10-14); 2.2x the same period a year earlier
18 Oct 2022Sharp changeShort interest spike: short interest spike, 2.7M vs usual 1.3M (2022-09-30); 1.9x the same period a year earlier
10 Aug 20228-K and other filingsDirector or officer change
21 Jul 2022Sharp changeLobbying on a new issue: lobbying on a new issue: PHA (2022-06-30)
19 Jul 20228-K and other filingsDirector or officer change
15 Jul 20228-K and other filingsDelisting notice or listing transfer
11 Jun 2022Sharp changeClustered insider buying: clustered insider buying (4 independent filers, 4 filing(s) in 30 days, value_usd total 148K)
17 May 20228-K and other filingsDirector or officer change
17 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Jun 2022: $152K published
Month from 1 Mar 2024: -$430K published
Month from 1 Nov 2024: -$214 published
Month from 1 Sep 2025: -$1.0M published
Month from 1 Oct 2025: -$686K published
Month from 1 Mar 2026: -$1.7M published
Month from 1 May 2026: -$35K published
Month from 1 Jun 2026: -$230K published
Month from 1 Jul 2026: -$100K published
Month from 1 Aug 2026: -$107K published
Month from 1 Sep 2026: -$166K published
Month from 1 Oct 2026: -$106K published
Month from 1 Nov 2026: $74K published
Revenue per quarter
Quarter ended 31 Dec 2021: $11.1M, +55% on a year earlier; public on 9 Mar 2022
Quarter ended 31 Mar 2022: $12.3M, +10% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $13.3M, -14% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $11.5M, -14% on a year earlier; public on 2 Nov 2022
Quarter ended 31 Dec 2022: $10.7M, -3.6% on a year earlier; public on 1 Apr 2023
Quarter ended 31 Mar 2023: $11.1M, -9.3% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $13.2M, -0.2% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $13.0M, +13% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $13.2M, +24% on a year earlier; public on 6 Mar 2024
Quarter ended 31 Mar 2024: $12.1M, +8.3% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $20.1M, +52% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $13.5M, +4.2% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Dec 2024: $11.9M, -10% on a year earlier; public on 6 Mar 2025
Quarter ended 31 Mar 2025: $8.7M, -28% on a year earlier; public on 13 May 2025
Quarter ended 30 Jun 2025: $10.0M, -50% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $12.8M, -5.4% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $13.0M, +9.7% on a year earlier; public on 5 Mar 2026
Quarter ended 31 Mar 2026: $14.4M, +66% on a year earlier; public on 14 May 2026
Quarter ended 30 Jun 2026: $13.8M, +38% on a year earlier; public on 12 Aug 2026
Quarter ended 30 Sep 2026: $7.6M, -41% on a year earlier; public on 4 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $533K, +126% on a year earlier; public on 9 Mar 2022
Quarter ended 31 Mar 2022: $104K, +1.0% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $677K, +249% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $217K, +161% on a year earlier; public on 2 Nov 2022
Quarter ended 31 Dec 2022: $26K, -95% on a year earlier; public on 1 Apr 2023
Quarter ended 31 Mar 2023: $2K, -98% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $826K, +22% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $151K, -30% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $16K, -38% on a year earlier; public on 6 Mar 2024
Quarter ended 31 Mar 2024: $29K, +1350% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $35K, -96% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $80K, -47% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Dec 2024: $15K, -6.2% on a year earlier; public on 6 Mar 2025
Quarter ended 31 Mar 2025: $135K, +366% on a year earlier; public on 13 May 2025
Quarter ended 30 Jun 2025: $107K, +206% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $235K, +194% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $85K, +467% on a year earlier; public on 5 Mar 2026
Quarter ended 31 Mar 2026: $52K, -61% on a year earlier; public on 14 May 2026
Quarter ended 30 Jun 2026: $212K, +98% on a year earlier; public on 12 Aug 2026
Quarter ended 30 Sep 2026: $584K, +149% on a year earlier; public on 4 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 49; public on 14 Feb 2022
31 Mar 2022 report: 48; public on 16 May 2022
30 Jun 2022 report: 44; public on 15 Aug 2022
30 Sep 2022 report: 45; public on 14 Nov 2022
31 Dec 2022 report: 33; public on 14 Feb 2023
31 Mar 2023 report: 32; public on 15 May 2023
30 Jun 2023 report: 51; public on 14 Aug 2023
30 Sep 2023 report: 45; public on 14 Nov 2023
31 Dec 2023 report: 55; public on 14 Feb 2024
31 Mar 2024 report: 95; public on 15 May 2024
30 Jun 2024 report: 88; public on 14 Aug 2024
30 Sep 2024 report: 114; public on 14 Nov 2024
31 Dec 2024 report: 114; public on 14 Feb 2025
31 Mar 2025 report: 118; public on 15 May 2025
30 Jun 2025 report: 111; public on 14 Aug 2025
30 Sep 2025 report: 143; public on 14 Nov 2025
31 Dec 2025 report: 172; public on 17 Feb 2026
31 Mar 2026 report: 175; public on 15 May 2026
30 Jun 2026 report: 183; public on 14 Aug 2026
30 Sep 2026 report: 188; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jul 2022: $45K published
Quarter from 1 Oct 2022: $45K published
Quarter from 1 Jan 2023: $45K published
Quarter from 1 Apr 2023: $45K published
Quarter from 1 Jul 2023: $45K published
Quarter from 1 Oct 2023: $45K published
Quarter from 1 Jan 2024: $45K published
Quarter from 1 Apr 2024: $45K published
Quarter from 1 Apr 2025: $20K published
Quarter from 1 Jul 2025: $30K published
Quarter from 1 Oct 2025: $50K published
Quarter from 1 Jan 2026: $60K published
Quarter from 1 Apr 2026: $60K published
Quarter from 1 Jul 2026: $60K published
Quarter from 1 Oct 2026: $60K published

What is unusual now

  • Made public in the last 90 days: it reported revenue of $7.6M for the quarter ended 30 Sep 2026, 41% below the same quarter last year.
  • Quarterly revenue change: reported revenue of $7.6M for the quarter ended 30 Sep 2026, 41% below the same quarter last year Public on 5 Nov 2026.
  • Insider net buying (open market): Insiders sold a net $2.3M in the last 12 months (the 12 months before: -$1.7M).
  • Capital spending per quarter: Capital spending $584K in the latest quarter, +149% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 61 insider trades

Last 90 days: 4 sales, $297K; 1 purchase, $99K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
16 Nov 2026Matthew W. DavisChief Development OfficerSellplanned in advance (10b5-1)7,197$3.55$26KForm 4
12 Nov 2026Richard J DalyDirectorBuy28,025$3.54$99KForm 4
16 Oct 2026Daniel BarberPresident and CEOSellplanned in advance (10b5-1)25,000$4.22$106KForm 4
16 Sep 2026Daniel BarberPresident and CEOSellplanned in advance (10b5-1)25,000$4.82$120KForm 4
11 Sep 2026Sherry KorczynskiChief Commercial OfficerSellplanned in advance (10b5-1); after exercising options8,750$5.22$46KForm 4
18 Aug 2026Daniel BarberPresident and CEOSellplanned in advance (10b5-1)25,000$4.29$107KForm 4
17 Jul 2026Daniel BarberPresident and CEOSellplanned in advance (10b5-1)25,000$4.01$100KForm 4
24 Jun 2026Julie KropDirectorSellplanned in advance (10b5-1); after exercising options25,000$5.02$126KForm 4

188 institutions reported shares at the end of Q3 2026, 60% of the shares outstanding; 21 opened a position, 19 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Bratton Capital Management, L.P.9.8M7.81%$45.4MNo change
BlackRock, Inc.8.2M6.53%$38.0M+144K+1.8%
RTW Investments, LP7.4M5.91%$34.4MNo change
Vanguard Capital Management LLC4.8M3.81%$22.2M+200K+4.4%
State Street Corp3.5M2.77%$16.1M+553K+19%
Federated Hermes, Inc.3.2M2.54%$14.8M+85K+2.7%
Geode Capital Management, LLC2.9M2.30%$13.4M+273K+10%
Samsara Biocapital, LLC2.4M1.94%$11.3M-66K-2.6%
Rosalind Advisors, Inc.2.0M1.59%$9.3M+1.8M+700%
HRT Financial LP1.9M1.55%+1.6M+465%

Company events

All 47 company events

In 12 months: 3 major agreements, 2 director or officer changes, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
14 Oct 2026Signed a major agreement8-K
29 Sep 2026Director or officer change8-K
13 May 2026Signed a major agreement; A major agreement endedSame filing: took on new debt, sold shares privately8-K
20 Mar 2026Director or officer change8-K
4 Mar 2026Signed a major agreementSame filing: sold shares privately8-K
14 Aug 2025Signed a major agreement8-K
14 Aug 2025Signed a major agreement8-K
7 Nov 2024Director or officer change8-K

Reported lobbying spend: $60K in Q3 2026, $60K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Jul 2025NewBracewell LLPfor Aquestive TherapeuticsIssues related to Poison Prevention Packaging ActConsumer safetyFiling
30 Apr 2023EndedSteptoe LLPfor Aquestive Therapeutics, Inc.Not statedFiling
1 Jan 2023EndedRubicon Advisors, LLCfor Aquestive Therapeutics, IncH.R, 1629/S 250: Fairness in Orphan Drug Exclusivity ActPharmacyFiling
7 Jun 2021NewRubicon Advisors, LLCfor Aquestive Therapeutics, IncH.R. 1629/S 250: Fairness in Orphan Drug Exclusivity ActPharmacyFiling
20 May 2019NewSteptoe LLPfor Aquestive Therapeutics, Inc.Issues related to the FDA and the Orphan Drug Program.Health issuesFiling

The 5 newest of 126 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

18 Nov 2025confirmed

Confirmed across sources Lobbying and Short interest and volume

Aquestive Therapeutics (AQST): lobbying on a new issue, while it had 24.1M shares sold short in the 31 Dec 2025 report, 2.3× the same report last year. Two unrelated kinds of activity within 134 days.

  • Lobbying: Lobbying on a new issue, became public on 20 Oct 2025
  • Short interest and volume: Short interest spike, became public on 13 Nov 2025
  • Short interest and volume: Short interest spike, became public on 26 Nov 2025
  • Short interest and volume: Short interest spike, became public on 10 Dec 2025
  • Short interest and volume: Short interest spike, became public on 25 Dec 2025
  • Short interest and volume: Short interest spike, became public on 13 Jan 2026
  • Short interest and volume: Short interest spike, became public on 28 Jan 2026
  • Short interest and volume: Short interest spike, became public on 11 Feb 2026
  • Short interest and volume: Short interest spike, became public on 26 Feb 2026
2024-12-31: 10.5M2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M2025-12-15: 21.9M2025-12-31: 24.1M
The 31 Dec 2025 report against the 24 reports before it. this reportearliernormal: 10.4M
See the evidence (9 changes)

Lobbying: Lobbying on a new issue became public on 20 Oct 2025

Aquestive Therapeutics lobbying on a new issue.

New
['CSP']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4690060

Short interest and volume: Short interest spike became public on 13 Nov 2025

Aquestive Therapeutics had 14.7M shares sold short in the 31 Oct 2025 report, 1.5× the same report last year.

This period
14.7M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
10.0M
Typical spread (median absolute deviation)
521K
How far from its usual level
+4.7
Same report last year
10.1M
History used
2,649 days
2024-10-31: 10.1M2024-11-15: 10.0M2024-11-29: 10.2M2024-12-13: 9.7M2024-12-31: 10.5M2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M
the 31 Oct 2025 report24 earlier reportsnormal: 10.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Nov 2025

Aquestive Therapeutics had 19.2M shares sold short in the 14 Nov 2025 report, 1.9× the same report last year.

This period
19.2M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
10.0M
Typical spread (median absolute deviation)
590K
How far from its usual level
+9.2
Same report last year
10.0M
History used
2,663 days
2024-11-15: 10.0M2024-11-29: 10.2M2024-12-13: 9.7M2024-12-31: 10.5M2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M
the 14 Nov 2025 report24 earlier reportsnormal: 10.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Dec 2025

Aquestive Therapeutics had 19.8M shares sold short in the 28 Nov 2025 report, 2.0× the same report last year.

This period
19.8M (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
10.1M
Typical spread (median absolute deviation)
745K
How far from its usual level
+8.8
Same report last year
10.2M
History used
2,677 days
2024-11-29: 10.2M2024-12-13: 9.7M2024-12-31: 10.5M2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M
the 28 Nov 2025 report24 earlier reportsnormal: 10.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Dec 2025

Aquestive Therapeutics had 21.9M shares sold short in the 15 Dec 2025 report, 2.3× the same report last year.

This period
21.9M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
10.1M
Typical spread (median absolute deviation)
906K
How far from its usual level
+8.8
Same report last year
9.7M
History used
2,694 days
2024-12-13: 9.7M2024-12-31: 10.5M2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M2025-12-15: 21.9M
the 15 Dec 2025 report24 earlier reportsnormal: 10.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 13 Jan 2026

Aquestive Therapeutics had 24.1M shares sold short in the 31 Dec 2025 report, 2.3× the same report last year.

This period
24.1M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
10.4M
Typical spread (median absolute deviation)
931K
How far from its usual level
+10.0
Same report last year
10.5M
History used
2,710 days
2024-12-31: 10.5M2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M2025-12-15: 21.9M2025-12-31: 24.1M
the 31 Dec 2025 report24 earlier reportsnormal: 10.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 Jan 2026

Aquestive Therapeutics had 20.3M shares sold short in the 15 Jan 2026 report, 1.7× the same report last year.

This period
20.3M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+5.5
Same report last year
11.8M
History used
2,725 days
2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M2025-12-15: 21.9M2025-12-31: 24.1M2026-01-15: 20.3M
the 15 Jan 2026 report24 earlier reportsnormal: 10.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Feb 2026

Aquestive Therapeutics had 20.4M shares sold short in the 30 Jan 2026 report, 1.8× the same report last year.

This period
20.4M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+5.3
Same report last year
11.1M
History used
2,740 days
2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M2025-12-15: 21.9M2025-12-31: 24.1M2026-01-15: 20.3M2026-01-30: 20.4M
the 30 Jan 2026 report24 earlier reportsnormal: 10.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Feb 2026

Aquestive Therapeutics had 20.0M shares sold short in the 13 Feb 2026 report, 2.0× the same report last year.

This period
20.0M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
1.3M
How far from its usual level
+4.9
Same report last year
10.0M
History used
2,754 days
2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M2025-12-15: 21.9M2025-12-31: 24.1M2026-01-15: 20.3M2026-01-30: 20.4M2026-02-13: 20.0M
the 13 Feb 2026 report24 earlier reportsnormal: 10.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

21 May 2024confirmed

Confirmed across sources Institutional holdings and Filings + Financials and Short interest and volume

Aquestive Therapeutics (AQST): saw 47 13F filers open a new position in the quarter ended 31 Mar 2024, 9.4× the same quarter last year; it also reported revenue of $20.1M for the quarter ended 30 Jun 2024, 1.5× the same quarter last year; and it had 11.1M shares sold short in the 30 Sep 2024 report, 5.4× the same report last year. Three unrelated kinds of activity within 182 days.

  • Short interest and volume: Short interest spike, became public on 25 Apr 2024
  • Short interest and volume: Short interest spike, became public on 10 May 2024
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2024
  • Short interest and volume: Short interest spike, became public on 25 May 2024
  • Short interest and volume: Short interest spike, became public on 12 Jun 2024
  • Short interest and volume: Short interest spike, became public on 27 Jun 2024
  • Short interest and volume: Short interest spike, became public on 11 Jul 2024
  • Short interest and volume: Short interest spike, became public on 25 Jul 2024
  • Financials: Quarterly revenue change, became public on 13 Aug 2024
  • Short interest and volume: Short interest spike, became public on 10 Aug 2024
  • Short interest and volume: Short interest spike, became public on 27 Aug 2024
  • Short interest and volume: Short interest spike, became public on 12 Sep 2024
  • Short interest and volume: Short interest spike, became public on 25 Sep 2024
  • Short interest and volume: Short interest spike, became public on 10 Oct 2024
  • Short interest and volume: Short interest spike, became public on 25 Oct 2024
2022-03-31: 52022-06-30: 42022-09-30: 82022-12-31: 12023-03-31: 52023-06-30: 222023-09-30: 52023-12-31: 122024-03-31: 47
The quarter ended 31 Mar 2024 against the 8 quarters before it. this quarterearliernormal: 5
See the evidence (15 changes)

Short interest and volume: Short interest spike became public on 25 Apr 2024

Aquestive Therapeutics had 4.0M shares sold short in the 15 Apr 2024 report, 2.1× the same report last year.

This period
4.0M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
92K
How far from its usual level
+10.6
Same report last year
1.9M
History used
2,085 days
2023-04-14: 1.9M2023-04-28: 1.8M2023-05-15: 1.9M2023-05-31: 2.0M2023-06-15: 2.2M2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M
the 15 Apr 2024 report24 earlier reportsnormal: 1.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 May 2024

Aquestive Therapeutics had 5.3M shares sold short in the 30 Apr 2024 report, 2.9× the same report last year.

This period
5.3M (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
95K
How far from its usual level
+17.0
Same report last year
1.8M
History used
2,100 days
2023-04-28: 1.8M2023-05-15: 1.9M2023-05-31: 2.0M2023-06-15: 2.2M2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M
the 30 Apr 2024 report24 earlier reportsnormal: 2.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 15 May 2024

Aquestive Therapeutics saw 47 13F filers open a new position in the quarter ended 31 Mar 2024, 9.4× the same quarter last year.

This period
47 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
5
Typical spread (median absolute deviation)
2
How far from its usual level
+14.0
Same quarter last year
5
History used
2,009 days
2022-03-31: 52022-06-30: 42022-09-30: 82022-12-31: 12023-03-31: 52023-06-30: 222023-09-30: 52023-12-31: 122024-03-31: 47
the quarter ended 31 Mar 20248 earlier quartersnormal: 5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 25 May 2024

Aquestive Therapeutics had 6.2M shares sold short in the 15 May 2024 report, 3.2× the same report last year.

This period
6.2M (the 15 May 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
90K
How far from its usual level
+21.6
Same report last year
1.9M
History used
2,115 days
2023-05-15: 1.9M2023-05-31: 2.0M2023-06-15: 2.2M2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M
the 15 May 2024 report24 earlier reportsnormal: 2.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Jun 2024

Aquestive Therapeutics had 6.7M shares sold short in the 31 May 2024 report, 3.4× the same report last year.

This period
6.7M (the 31 May 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
96K
How far from its usual level
+24.0
Same report last year
2.0M
History used
2,131 days
2023-05-31: 2.0M2023-06-15: 2.2M2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M
the 31 May 2024 report24 earlier reportsnormal: 2.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Jun 2024

Aquestive Therapeutics had 7.2M shares sold short in the 14 Jun 2024 report, 3.2× the same report last year.

This period
7.2M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
123K
How far from its usual level
+26.1
Same report last year
2.2M
History used
2,145 days
2023-06-15: 2.2M2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M
the 14 Jun 2024 report24 earlier reportsnormal: 2.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Jul 2024

Aquestive Therapeutics had 7.6M shares sold short in the 28 Jun 2024 report, 4.4× the same report last year.

This period
7.6M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
123K
How far from its usual level
+28.4
Same report last year
1.7M
History used
2,159 days
2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M
the 28 Jun 2024 report24 earlier reportsnormal: 2.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Jul 2024

Aquestive Therapeutics had 10.4M shares sold short in the 15 Jul 2024 report, 5.4× the same report last year.

This period
10.4M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
147K
How far from its usual level
+38.3
Same report last year
1.9M
History used
2,176 days
2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M
the 15 Jul 2024 report24 earlier reportsnormal: 2.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 13 Aug 2024

Aquestive Therapeutics reported revenue of $20.1M for the quarter ended 30 Jun 2024, 1.5× the same quarter last year.

This period
$20.1M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$12.5M
Typical spread (median absolute deviation)
$726K
How far from its usual level
+6.0
Same quarter last year
$13.2M
History used
2,648 days
2022-06-30: $13.3M2022-09-30: $11.5M2022-12-31: $10.7M2023-03-31: $11.1M2023-06-30: $13.2M2023-09-30: $13.0M2023-12-31: $13.2M2024-03-31: $12.1M2024-06-30: $20.1M
the quarter ended 30 Jun 20248 earlier quartersnormal: $12.5M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 10 Aug 2024

Aquestive Therapeutics had 10.8M shares sold short in the 31 Jul 2024 report, 5.3× the same report last year.

This period
10.8M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
205K
How far from its usual level
+28.8
Same report last year
2.0M
History used
2,192 days
2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M
the 31 Jul 2024 report24 earlier reportsnormal: 2.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Aug 2024

Aquestive Therapeutics had 10.8M shares sold short in the 15 Aug 2024 report, 5.5× the same report last year.

This period
10.8M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
226K
How far from its usual level
+26.1
Same report last year
2.0M
History used
2,207 days
2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M2024-08-15: 10.8M
the 15 Aug 2024 report24 earlier reportsnormal: 2.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Sep 2024

Aquestive Therapeutics had 10.8M shares sold short in the 30 Aug 2024 report, 5.9× the same report last year.

This period
10.8M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
244K
How far from its usual level
+24.2
Same report last year
1.8M
History used
2,222 days
2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M2024-08-15: 10.8M2024-08-30: 10.8M
the 30 Aug 2024 report24 earlier reportsnormal: 2.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Sep 2024

Aquestive Therapeutics had 10.8M shares sold short in the 13 Sep 2024 report, 5.8× the same report last year.

This period
10.8M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
340K
How far from its usual level
+17.1
Same report last year
1.8M
History used
2,236 days
2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M2024-08-15: 10.8M2024-08-30: 10.8M2024-09-13: 10.8M
the 13 Sep 2024 report24 earlier reportsnormal: 2.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Oct 2024

Aquestive Therapeutics had 11.1M shares sold short in the 30 Sep 2024 report, 5.4× the same report last year.

This period
11.1M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
520K
How far from its usual level
+11.4
Same report last year
2.0M
History used
2,253 days
2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M2024-08-15: 10.8M2024-08-30: 10.8M2024-09-13: 10.8M2024-09-30: 11.1M
the 30 Sep 2024 report24 earlier reportsnormal: 2.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Oct 2024

Aquestive Therapeutics had 10.8M shares sold short in the 15 Oct 2024 report, 5.4× the same report last year.

This period
10.8M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
3.2M
Typical spread (median absolute deviation)
1.4M
How far from its usual level
+3.7
Same report last year
2.0M
History used
2,268 days
2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M2024-08-15: 10.8M2024-08-30: 10.8M2024-09-13: 10.8M2024-09-30: 11.1M2024-10-15: 10.8M
the 15 Oct 2024 report24 earlier reportsnormal: 3.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 12 Nov 2026Insiders record

    Daly Richard J (director) bought 28,025 shares of AQST ($99,331)

  2. 5 Nov 2026Financials change

    reported revenue of $7.6M for the quarter ended 30 Sep 2026, 41% below the same quarter last year.

    Same quarter last year: $12.8M; its normal quarter is $12.9M.

    See the evidence
    This period
    $7.6M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $12.9M
    Typical spread (median absolute deviation)
    $976K
    How far from its usual level
    -3.7
    Same quarter last year
    $12.8M
    History used
    3,470 days
    2024-09-30: $13.5M2024-12-31: $11.9M2025-03-31: $8.7M2025-06-30: $10.0M2025-09-30: $12.8M2025-12-31: $13.0M2026-03-31: $14.4M2026-06-30: $13.8M2026-09-30: $7.6M
    the quarter ended 30 Sep 20268 earlier quartersnormal: $12.9M

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  3. 29 Sep 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 29 Sep 2026Filings record

    Director or officer change

  5. 13 May 2026Filings record

    A major agreement ended

  6. 20 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  7. 20 Mar 2026Filings record

    Director or officer change

  8. 26 Feb 2026Short interest and volume change

    had 20.0M shares sold short in the 13 Feb 2026 report, 2.0× the same report last year.

    Same report last year: 10.0M; its normal report is 10.7M.

    See the evidence
    This period
    20.0M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    10.7M
    Typical spread (median absolute deviation)
    1.3M
    How far from its usual level
    +4.9
    Same report last year
    10.0M
    History used
    2,754 days
    2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M2025-12-15: 21.9M2025-12-31: 24.1M2026-01-15: 20.3M2026-01-30: 20.4M2026-02-13: 20.0M
    the 13 Feb 2026 report24 earlier reportsnormal: 10.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 11 Feb 2026Short interest and volume change

    had 20.4M shares sold short in the 30 Jan 2026 report, 1.8× the same report last year.

    Same report last year: 11.1M; its normal report is 10.7M.

    See the evidence
    This period
    20.4M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    10.7M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +5.3
    Same report last year
    11.1M
    History used
    2,740 days
    2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M2025-12-15: 21.9M2025-12-31: 24.1M2026-01-15: 20.3M2026-01-30: 20.4M
    the 30 Jan 2026 report24 earlier reportsnormal: 10.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 28 Jan 2026Short interest and volume change

    had 20.3M shares sold short in the 15 Jan 2026 report, 1.7× the same report last year.

    Same report last year: 11.8M; its normal report is 10.7M.

    See the evidence
    This period
    20.3M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    10.7M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +5.5
    Same report last year
    11.8M
    History used
    2,725 days
    2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M2025-12-15: 21.9M2025-12-31: 24.1M2026-01-15: 20.3M
    the 15 Jan 2026 report24 earlier reportsnormal: 10.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 13 Jan 2026Short interest and volume change

    had 24.1M shares sold short in the 31 Dec 2025 report, 2.3× the same report last year.

    Same report last year: 10.5M; its normal report is 10.4M.

    See the evidence
    This period
    24.1M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    10.4M
    Typical spread (median absolute deviation)
    931K
    How far from its usual level
    +10.0
    Same report last year
    10.5M
    History used
    2,710 days
    2024-12-31: 10.5M2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M2025-12-15: 21.9M2025-12-31: 24.1M
    the 31 Dec 2025 report24 earlier reportsnormal: 10.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 25 Dec 2025Short interest and volume change

    had 21.9M shares sold short in the 15 Dec 2025 report, 2.3× the same report last year.

    Same report last year: 9.7M; its normal report is 10.1M.

    See the evidence
    This period
    21.9M (the 15 Dec 2025 report)
    Normal report (median of 24 earlier)
    10.1M
    Typical spread (median absolute deviation)
    906K
    How far from its usual level
    +8.8
    Same report last year
    9.7M
    History used
    2,694 days
    2024-12-13: 9.7M2024-12-31: 10.5M2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M2025-12-15: 21.9M
    the 15 Dec 2025 report24 earlier reportsnormal: 10.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 10 Dec 2025Short interest and volume change

    had 19.8M shares sold short in the 28 Nov 2025 report, 2.0× the same report last year.

    Same report last year: 10.2M; its normal report is 10.1M.

    See the evidence
    This period
    19.8M (the 28 Nov 2025 report)
    Normal report (median of 24 earlier)
    10.1M
    Typical spread (median absolute deviation)
    745K
    How far from its usual level
    +8.8
    Same report last year
    10.2M
    History used
    2,677 days
    2024-11-29: 10.2M2024-12-13: 9.7M2024-12-31: 10.5M2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M
    the 28 Nov 2025 report24 earlier reportsnormal: 10.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 26 Nov 2025Short interest and volume change

    had 19.2M shares sold short in the 14 Nov 2025 report, 1.9× the same report last year.

    Same report last year: 10.0M; its normal report is 10.0M.

    See the evidence
    This period
    19.2M (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    10.0M
    Typical spread (median absolute deviation)
    590K
    How far from its usual level
    +9.2
    Same report last year
    10.0M
    History used
    2,663 days
    2024-11-15: 10.0M2024-11-29: 10.2M2024-12-13: 9.7M2024-12-31: 10.5M2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M
    the 14 Nov 2025 report24 earlier reportsnormal: 10.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 18 Nov 2025several at once

    lobbying on a new issue, while it had 24.1M shares sold short in the 31 Dec 2025 report, 2.3× the same report last year. Two unrelated kinds of activity within 134 days.

    See the evidence (9 changes)

    Lobbying: Lobbying on a new issue became public on 20 Oct 2025

    Aquestive Therapeutics lobbying on a new issue.

    New
    ['CSP']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4690060

    Short interest and volume: Short interest spike became public on 13 Nov 2025

    Aquestive Therapeutics had 14.7M shares sold short in the 31 Oct 2025 report, 1.5× the same report last year.

    This period
    14.7M (the 31 Oct 2025 report)
    Normal report (median of 24 earlier)
    10.0M
    Typical spread (median absolute deviation)
    521K
    How far from its usual level
    +4.7
    Same report last year
    10.1M
    History used
    2,649 days
    2024-10-31: 10.1M2024-11-15: 10.0M2024-11-29: 10.2M2024-12-13: 9.7M2024-12-31: 10.5M2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M
    the 31 Oct 2025 report24 earlier reportsnormal: 10.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Nov 2025

    Aquestive Therapeutics had 19.2M shares sold short in the 14 Nov 2025 report, 1.9× the same report last year.

    This period
    19.2M (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    10.0M
    Typical spread (median absolute deviation)
    590K
    How far from its usual level
    +9.2
    Same report last year
    10.0M
    History used
    2,663 days
    2024-11-15: 10.0M2024-11-29: 10.2M2024-12-13: 9.7M2024-12-31: 10.5M2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M
    the 14 Nov 2025 report24 earlier reportsnormal: 10.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Dec 2025

    Aquestive Therapeutics had 19.8M shares sold short in the 28 Nov 2025 report, 2.0× the same report last year.

    This period
    19.8M (the 28 Nov 2025 report)
    Normal report (median of 24 earlier)
    10.1M
    Typical spread (median absolute deviation)
    745K
    How far from its usual level
    +8.8
    Same report last year
    10.2M
    History used
    2,677 days
    2024-11-29: 10.2M2024-12-13: 9.7M2024-12-31: 10.5M2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M
    the 28 Nov 2025 report24 earlier reportsnormal: 10.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Dec 2025

    Aquestive Therapeutics had 21.9M shares sold short in the 15 Dec 2025 report, 2.3× the same report last year.

    This period
    21.9M (the 15 Dec 2025 report)
    Normal report (median of 24 earlier)
    10.1M
    Typical spread (median absolute deviation)
    906K
    How far from its usual level
    +8.8
    Same report last year
    9.7M
    History used
    2,694 days
    2024-12-13: 9.7M2024-12-31: 10.5M2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M2025-12-15: 21.9M
    the 15 Dec 2025 report24 earlier reportsnormal: 10.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 13 Jan 2026

    Aquestive Therapeutics had 24.1M shares sold short in the 31 Dec 2025 report, 2.3× the same report last year.

    This period
    24.1M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    10.4M
    Typical spread (median absolute deviation)
    931K
    How far from its usual level
    +10.0
    Same report last year
    10.5M
    History used
    2,710 days
    2024-12-31: 10.5M2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M2025-12-15: 21.9M2025-12-31: 24.1M
    the 31 Dec 2025 report24 earlier reportsnormal: 10.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 28 Jan 2026

    Aquestive Therapeutics had 20.3M shares sold short in the 15 Jan 2026 report, 1.7× the same report last year.

    This period
    20.3M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    10.7M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +5.5
    Same report last year
    11.8M
    History used
    2,725 days
    2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M2025-12-15: 21.9M2025-12-31: 24.1M2026-01-15: 20.3M
    the 15 Jan 2026 report24 earlier reportsnormal: 10.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Feb 2026

    Aquestive Therapeutics had 20.4M shares sold short in the 30 Jan 2026 report, 1.8× the same report last year.

    This period
    20.4M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    10.7M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +5.3
    Same report last year
    11.1M
    History used
    2,740 days
    2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M2025-12-15: 21.9M2025-12-31: 24.1M2026-01-15: 20.3M2026-01-30: 20.4M
    the 30 Jan 2026 report24 earlier reportsnormal: 10.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Feb 2026

    Aquestive Therapeutics had 20.0M shares sold short in the 13 Feb 2026 report, 2.0× the same report last year.

    This period
    20.0M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    10.7M
    Typical spread (median absolute deviation)
    1.3M
    How far from its usual level
    +4.9
    Same report last year
    10.0M
    History used
    2,754 days
    2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M2025-11-14: 19.2M2025-11-28: 19.8M2025-12-15: 21.9M2025-12-31: 24.1M2026-01-15: 20.3M2026-01-30: 20.4M2026-02-13: 20.0M
    the 13 Feb 2026 report24 earlier reportsnormal: 10.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  16. 13 Nov 2025Short interest and volume change

    had 14.7M shares sold short in the 31 Oct 2025 report, 1.5× the same report last year.

    Same report last year: 10.1M; its normal report is 10.0M.

    See the evidence
    This period
    14.7M (the 31 Oct 2025 report)
    Normal report (median of 24 earlier)
    10.0M
    Typical spread (median absolute deviation)
    521K
    How far from its usual level
    +4.7
    Same report last year
    10.1M
    History used
    2,649 days
    2024-10-31: 10.1M2024-11-15: 10.0M2024-11-29: 10.2M2024-12-13: 9.7M2024-12-31: 10.5M2025-01-15: 11.8M2025-01-31: 11.1M2025-02-14: 10.0M2025-02-28: 10.0M2025-03-14: 10.2M2025-03-31: 10.0M2025-04-15: 9.9M2025-04-30: 9.4M2025-05-15: 9.8M2025-05-30: 11.1M2025-06-13: 12.0M2025-06-30: 11.2M2025-07-15: 10.0M2025-07-31: 9.4M2025-08-15: 8.4M2025-08-29: 9.3M2025-09-15: 8.9M2025-09-30: 11.6M2025-10-15: 12.3M2025-10-31: 14.7M
    the 31 Oct 2025 report24 earlier reportsnormal: 10.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 20 Oct 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['CSP']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4690060
  18. 22 Jul 2025Lobbying record

    AQUESTIVE THERAPEUTICS: new lobbying registration (BRACEWELL LLP) (dated 1 Jul 2025)

  19. 13 May 2025Financials change

    reported revenue of $8.7M for the quarter ended 31 Mar 2025, 28% below the same quarter last year.

    Same quarter last year: $12.1M; its normal quarter is $13.1M.

    See the evidence
    This period
    $8.7M (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    $13.1M
    Typical spread (median absolute deviation)
    $744K
    How far from its usual level
    -3.3
    Same quarter last year
    $12.1M
    History used
    2,922 days
    2023-03-31: $11.1M2023-06-30: $13.2M2023-09-30: $13.0M2023-12-31: $13.2M2024-03-31: $12.1M2024-06-30: $20.1M2024-09-30: $13.5M2024-12-31: $11.9M2025-03-31: $8.7M
    the quarter ended 31 Mar 20258 earlier quartersnormal: $13.1M

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  20. 7 Nov 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 7 Nov 2024Filings record

    Director or officer change

  22. 25 Oct 2024Short interest and volume change

    had 10.8M shares sold short in the 15 Oct 2024 report, 5.4× the same report last year.

    Same report last year: 2.0M; its normal report is 3.2M.

    See the evidence
    This period
    10.8M (the 15 Oct 2024 report)
    Normal report (median of 24 earlier)
    3.2M
    Typical spread (median absolute deviation)
    1.4M
    How far from its usual level
    +3.7
    Same report last year
    2.0M
    History used
    2,268 days
    2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M2024-08-15: 10.8M2024-08-30: 10.8M2024-09-13: 10.8M2024-09-30: 11.1M2024-10-15: 10.8M
    the 15 Oct 2024 report24 earlier reportsnormal: 3.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 10 Oct 2024Short interest and volume change

    had 11.1M shares sold short in the 30 Sep 2024 report, 5.4× the same report last year.

    Same report last year: 2.0M; its normal report is 2.3M.

    See the evidence
    This period
    11.1M (the 30 Sep 2024 report)
    Normal report (median of 24 earlier)
    2.3M
    Typical spread (median absolute deviation)
    520K
    How far from its usual level
    +11.4
    Same report last year
    2.0M
    History used
    2,253 days
    2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M2024-08-15: 10.8M2024-08-30: 10.8M2024-09-13: 10.8M2024-09-30: 11.1M
    the 30 Sep 2024 report24 earlier reportsnormal: 2.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 25 Sep 2024Short interest and volume change

    had 10.8M shares sold short in the 13 Sep 2024 report, 5.8× the same report last year.

    Same report last year: 1.8M; its normal report is 2.2M.

    See the evidence
    This period
    10.8M (the 13 Sep 2024 report)
    Normal report (median of 24 earlier)
    2.2M
    Typical spread (median absolute deviation)
    340K
    How far from its usual level
    +17.1
    Same report last year
    1.8M
    History used
    2,236 days
    2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M2024-08-15: 10.8M2024-08-30: 10.8M2024-09-13: 10.8M
    the 13 Sep 2024 report24 earlier reportsnormal: 2.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 12 Sep 2024Short interest and volume change

    had 10.8M shares sold short in the 30 Aug 2024 report, 5.9× the same report last year.

    Same report last year: 1.8M; its normal report is 2.1M.

    See the evidence
    This period
    10.8M (the 30 Aug 2024 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    244K
    How far from its usual level
    +24.2
    Same report last year
    1.8M
    History used
    2,222 days
    2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M2024-08-15: 10.8M2024-08-30: 10.8M
    the 30 Aug 2024 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 27 Aug 2024Short interest and volume change

    had 10.8M shares sold short in the 15 Aug 2024 report, 5.5× the same report last year.

    Same report last year: 2.0M; its normal report is 2.0M.

    See the evidence
    This period
    10.8M (the 15 Aug 2024 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    226K
    How far from its usual level
    +26.1
    Same report last year
    2.0M
    History used
    2,207 days
    2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M2024-08-15: 10.8M
    the 15 Aug 2024 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 13 Aug 2024Financials change

    reported revenue of $20.1M for the quarter ended 30 Jun 2024, 1.5× the same quarter last year.

    Same quarter last year: $13.2M; its normal quarter is $12.5M.

    See the evidence
    This period
    $20.1M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $12.5M
    Typical spread (median absolute deviation)
    $726K
    How far from its usual level
    +6.0
    Same quarter last year
    $13.2M
    History used
    2,648 days
    2022-06-30: $13.3M2022-09-30: $11.5M2022-12-31: $10.7M2023-03-31: $11.1M2023-06-30: $13.2M2023-09-30: $13.0M2023-12-31: $13.2M2024-03-31: $12.1M2024-06-30: $20.1M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $12.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  28. 10 Aug 2024Short interest and volume change

    had 10.8M shares sold short in the 31 Jul 2024 report, 5.3× the same report last year.

    Same report last year: 2.0M; its normal report is 2.0M.

    See the evidence
    This period
    10.8M (the 31 Jul 2024 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    205K
    How far from its usual level
    +28.8
    Same report last year
    2.0M
    History used
    2,192 days
    2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M
    the 31 Jul 2024 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 25 Jul 2024Short interest and volume change

    had 10.4M shares sold short in the 15 Jul 2024 report, 5.4× the same report last year.

    Same report last year: 1.9M; its normal report is 2.0M.

    See the evidence
    This period
    10.4M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    147K
    How far from its usual level
    +38.3
    Same report last year
    1.9M
    History used
    2,176 days
    2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M
    the 15 Jul 2024 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 21 Jul 2024Lobbying record

    AQUESTIVE THERAPEUTICS, INC: lobbying engagement terminated (RUBICON ADVISORS, LLC) (dated 1 Jan 2023)

  31. 11 Jul 2024Short interest and volume change

    had 7.6M shares sold short in the 28 Jun 2024 report, 4.4× the same report last year.

    Same report last year: 1.7M; its normal report is 2.0M.

    See the evidence
    This period
    7.6M (the 28 Jun 2024 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    123K
    How far from its usual level
    +28.4
    Same report last year
    1.7M
    History used
    2,159 days
    2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M
    the 28 Jun 2024 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 27 Jun 2024Short interest and volume change

    had 7.2M shares sold short in the 14 Jun 2024 report, 3.2× the same report last year.

    Same report last year: 2.2M; its normal report is 2.0M.

    See the evidence
    This period
    7.2M (the 14 Jun 2024 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    123K
    How far from its usual level
    +26.1
    Same report last year
    2.2M
    History used
    2,145 days
    2023-06-15: 2.2M2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M
    the 14 Jun 2024 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 12 Jun 2024Short interest and volume change

    had 6.7M shares sold short in the 31 May 2024 report, 3.4× the same report last year.

    Same report last year: 2.0M; its normal report is 2.0M.

    See the evidence
    This period
    6.7M (the 31 May 2024 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    96K
    How far from its usual level
    +24.0
    Same report last year
    2.0M
    History used
    2,131 days
    2023-05-31: 2.0M2023-06-15: 2.2M2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M
    the 31 May 2024 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 6 Jun 2024Filings record

    Director or officer change

  35. 25 May 2024Short interest and volume change

    had 6.2M shares sold short in the 15 May 2024 report, 3.2× the same report last year.

    Same report last year: 1.9M; its normal report is 2.0M.

    See the evidence
    This period
    6.2M (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    90K
    How far from its usual level
    +21.6
    Same report last year
    1.9M
    History used
    2,115 days
    2023-05-15: 1.9M2023-05-31: 2.0M2023-06-15: 2.2M2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M
    the 15 May 2024 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 21 May 2024several at once

    saw 47 13F filers open a new position in the quarter ended 31 Mar 2024, 9.4× the same quarter last year; it also reported revenue of $20.1M for the quarter ended 30 Jun 2024, 1.5× the same quarter last year; and it had 11.1M shares sold short in the 30 Sep 2024 report, 5.4× the same report last year. Three unrelated kinds of activity within 182 days.

    See the evidence (15 changes)

    Short interest and volume: Short interest spike became public on 25 Apr 2024

    Aquestive Therapeutics had 4.0M shares sold short in the 15 Apr 2024 report, 2.1× the same report last year.

    This period
    4.0M (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    1.9M
    Typical spread (median absolute deviation)
    92K
    How far from its usual level
    +10.6
    Same report last year
    1.9M
    History used
    2,085 days
    2023-04-14: 1.9M2023-04-28: 1.8M2023-05-15: 1.9M2023-05-31: 2.0M2023-06-15: 2.2M2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M
    the 15 Apr 2024 report24 earlier reportsnormal: 1.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 May 2024

    Aquestive Therapeutics had 5.3M shares sold short in the 30 Apr 2024 report, 2.9× the same report last year.

    This period
    5.3M (the 30 Apr 2024 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    95K
    How far from its usual level
    +17.0
    Same report last year
    1.8M
    History used
    2,100 days
    2023-04-28: 1.8M2023-05-15: 1.9M2023-05-31: 2.0M2023-06-15: 2.2M2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M
    the 30 Apr 2024 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 15 May 2024

    Aquestive Therapeutics saw 47 13F filers open a new position in the quarter ended 31 Mar 2024, 9.4× the same quarter last year.

    This period
    47 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +14.0
    Same quarter last year
    5
    History used
    2,009 days
    2022-03-31: 52022-06-30: 42022-09-30: 82022-12-31: 12023-03-31: 52023-06-30: 222023-09-30: 52023-12-31: 122024-03-31: 47
    the quarter ended 31 Mar 20248 earlier quartersnormal: 5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 25 May 2024

    Aquestive Therapeutics had 6.2M shares sold short in the 15 May 2024 report, 3.2× the same report last year.

    This period
    6.2M (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    90K
    How far from its usual level
    +21.6
    Same report last year
    1.9M
    History used
    2,115 days
    2023-05-15: 1.9M2023-05-31: 2.0M2023-06-15: 2.2M2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M
    the 15 May 2024 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 12 Jun 2024

    Aquestive Therapeutics had 6.7M shares sold short in the 31 May 2024 report, 3.4× the same report last year.

    This period
    6.7M (the 31 May 2024 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    96K
    How far from its usual level
    +24.0
    Same report last year
    2.0M
    History used
    2,131 days
    2023-05-31: 2.0M2023-06-15: 2.2M2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M
    the 31 May 2024 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 27 Jun 2024

    Aquestive Therapeutics had 7.2M shares sold short in the 14 Jun 2024 report, 3.2× the same report last year.

    This period
    7.2M (the 14 Jun 2024 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    123K
    How far from its usual level
    +26.1
    Same report last year
    2.2M
    History used
    2,145 days
    2023-06-15: 2.2M2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M
    the 14 Jun 2024 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Jul 2024

    Aquestive Therapeutics had 7.6M shares sold short in the 28 Jun 2024 report, 4.4× the same report last year.

    This period
    7.6M (the 28 Jun 2024 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    123K
    How far from its usual level
    +28.4
    Same report last year
    1.7M
    History used
    2,159 days
    2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M
    the 28 Jun 2024 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Jul 2024

    Aquestive Therapeutics had 10.4M shares sold short in the 15 Jul 2024 report, 5.4× the same report last year.

    This period
    10.4M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    147K
    How far from its usual level
    +38.3
    Same report last year
    1.9M
    History used
    2,176 days
    2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M
    the 15 Jul 2024 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 13 Aug 2024

    Aquestive Therapeutics reported revenue of $20.1M for the quarter ended 30 Jun 2024, 1.5× the same quarter last year.

    This period
    $20.1M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $12.5M
    Typical spread (median absolute deviation)
    $726K
    How far from its usual level
    +6.0
    Same quarter last year
    $13.2M
    History used
    2,648 days
    2022-06-30: $13.3M2022-09-30: $11.5M2022-12-31: $10.7M2023-03-31: $11.1M2023-06-30: $13.2M2023-09-30: $13.0M2023-12-31: $13.2M2024-03-31: $12.1M2024-06-30: $20.1M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $12.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 10 Aug 2024

    Aquestive Therapeutics had 10.8M shares sold short in the 31 Jul 2024 report, 5.3× the same report last year.

    This period
    10.8M (the 31 Jul 2024 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    205K
    How far from its usual level
    +28.8
    Same report last year
    2.0M
    History used
    2,192 days
    2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M
    the 31 Jul 2024 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 27 Aug 2024

    Aquestive Therapeutics had 10.8M shares sold short in the 15 Aug 2024 report, 5.5× the same report last year.

    This period
    10.8M (the 15 Aug 2024 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    226K
    How far from its usual level
    +26.1
    Same report last year
    2.0M
    History used
    2,207 days
    2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M2024-08-15: 10.8M
    the 15 Aug 2024 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 12 Sep 2024

    Aquestive Therapeutics had 10.8M shares sold short in the 30 Aug 2024 report, 5.9× the same report last year.

    This period
    10.8M (the 30 Aug 2024 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    244K
    How far from its usual level
    +24.2
    Same report last year
    1.8M
    History used
    2,222 days
    2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M2024-08-15: 10.8M2024-08-30: 10.8M
    the 30 Aug 2024 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Sep 2024

    Aquestive Therapeutics had 10.8M shares sold short in the 13 Sep 2024 report, 5.8× the same report last year.

    This period
    10.8M (the 13 Sep 2024 report)
    Normal report (median of 24 earlier)
    2.2M
    Typical spread (median absolute deviation)
    340K
    How far from its usual level
    +17.1
    Same report last year
    1.8M
    History used
    2,236 days
    2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M2024-08-15: 10.8M2024-08-30: 10.8M2024-09-13: 10.8M
    the 13 Sep 2024 report24 earlier reportsnormal: 2.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Oct 2024

    Aquestive Therapeutics had 11.1M shares sold short in the 30 Sep 2024 report, 5.4× the same report last year.

    This period
    11.1M (the 30 Sep 2024 report)
    Normal report (median of 24 earlier)
    2.3M
    Typical spread (median absolute deviation)
    520K
    How far from its usual level
    +11.4
    Same report last year
    2.0M
    History used
    2,253 days
    2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M2024-08-15: 10.8M2024-08-30: 10.8M2024-09-13: 10.8M2024-09-30: 11.1M
    the 30 Sep 2024 report24 earlier reportsnormal: 2.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Oct 2024

    Aquestive Therapeutics had 10.8M shares sold short in the 15 Oct 2024 report, 5.4× the same report last year.

    This period
    10.8M (the 15 Oct 2024 report)
    Normal report (median of 24 earlier)
    3.2M
    Typical spread (median absolute deviation)
    1.4M
    How far from its usual level
    +3.7
    Same report last year
    2.0M
    History used
    2,268 days
    2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M2024-05-15: 6.2M2024-05-31: 6.7M2024-06-14: 7.2M2024-06-28: 7.6M2024-07-15: 10.4M2024-07-31: 10.8M2024-08-15: 10.8M2024-08-30: 10.8M2024-09-13: 10.8M2024-09-30: 11.1M2024-10-15: 10.8M
    the 15 Oct 2024 report24 earlier reportsnormal: 3.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  37. 15 May 2024Institutional holdings change

    saw 47 13F filers open a new position in the quarter ended 31 Mar 2024, 9.4× the same quarter last year.

    Same quarter last year: 5; its normal quarter is 5.

    See the evidence
    This period
    47 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +14.0
    Same quarter last year
    5
    History used
    2,009 days
    2022-03-31: 52022-06-30: 42022-09-30: 82022-12-31: 12023-03-31: 52023-06-30: 222023-09-30: 52023-12-31: 122024-03-31: 47
    the quarter ended 31 Mar 20248 earlier quartersnormal: 5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  38. 10 May 2024Short interest and volume change

    had 5.3M shares sold short in the 30 Apr 2024 report, 2.9× the same report last year.

    Same report last year: 1.8M; its normal report is 2.0M.

    See the evidence
    This period
    5.3M (the 30 Apr 2024 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    95K
    How far from its usual level
    +17.0
    Same report last year
    1.8M
    History used
    2,100 days
    2023-04-28: 1.8M2023-05-15: 1.9M2023-05-31: 2.0M2023-06-15: 2.2M2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M2024-04-30: 5.3M
    the 30 Apr 2024 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 25 Apr 2024Short interest and volume change

    had 4.0M shares sold short in the 15 Apr 2024 report, 2.1× the same report last year.

    Same report last year: 1.9M; its normal report is 1.9M.

    See the evidence
    This period
    4.0M (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    1.9M
    Typical spread (median absolute deviation)
    92K
    How far from its usual level
    +10.6
    Same report last year
    1.9M
    History used
    2,085 days
    2023-04-14: 1.9M2023-04-28: 1.8M2023-05-15: 1.9M2023-05-31: 2.0M2023-06-15: 2.2M2023-06-30: 1.7M2023-07-14: 1.9M2023-07-31: 2.0M2023-08-15: 2.0M2023-08-31: 1.8M2023-09-15: 1.8M2023-09-29: 2.0M2023-10-13: 2.0M2023-10-31: 2.0M2023-11-15: 1.9M2023-11-30: 1.9M2023-12-15: 2.1M2023-12-29: 2.0M2024-01-12: 1.9M2024-01-31: 1.7M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 2.3M2024-03-28: 2.3M2024-04-15: 4.0M
    the 15 Apr 2024 report24 earlier reportsnormal: 1.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 1 Apr 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

Showing the newest 40 of 108 entries; narrow the window or the kind of data to see older ones.

Not listed: 201 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001398733
Ticker
AQST
Domain
aquestive.com
Hq location
NJ|WARREN| (1 unverified)
Lobbying client
aquestive therapeutics
Name
Aquestive Therapeutics, Inc., MonoSol Rx, Inc.
Uei
XBKKRRJPR255
  • Federal lobbying disclosures (LDA)5 records, 71 data points20 May 2019 to 30 Sep 2026
  • SEC Form 13F institutional holdings297 data points30 Sep 2018 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)188 records9 May 2018 to 3 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)645 data points31 Dec 2016 to 30 Oct 2026
  • SEC Form 4 insider transactions61 records, 160 data points26 Jul 2018 to 16 Nov 2026
  • FINRA short interest (twice monthly)593 data points31 Jul 2018 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026